WuXi Biologics revenue rises 16% to RMB10bn

WuXi Biologics reported 16.1% revenue growth to RMB10.0 billion for the first half of 2025, with adjusted net profit rising 11.6% to RMB2.8 billion. Gross profit margin expanded 360 basis points to 42.7%.

The company added a record 86 new integrated projects, bringing the total to 864. Commercial projects increased 50% to 24. Total backlog reached $20.3 billion.

WuXi Biologics raised its full-year 2025 revenue growth target to 14%-16%.